Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to $659.5 million.

  • NewAmsterdam Pharma Co N.V's Cash from Financing Activities rose 10058.62% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $472.4 million, marking a year-over-year increase of 132.64%. This contributed to the annual value of $659.5 million for FY2024, which is 7300.21% up from last year.
  • NewAmsterdam Pharma Co N.V's Cash from Financing Activities amounted to $659.5 million in FY2024, which was up 7,300.21% from $8.9 million recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Cash from Financing Activities registered a high of $659.5 million during FY2024, and its lowest value of $8.9 million during FY2023.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Cash from Financing Activities averaged around $353.4 million, with its median value being $391.9 million (2022).
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Cash from Financing Activities plummeted by 97.73% in 2023 and then spiked by 7,300.21% in 2024.
  • Yearly analysis of 5 years shows NewAmsterdam Pharma Co N.V's Cash from Financing Activities stood at $12.9 million in 2020, then skyrocketed by 555.36% to $84.7 million in 2021, then surged by 362.68% to $391.9 million in 2022, then tumbled by 97.73% to $8.9 million in 2023, then soared by 7,300.21% to $659.5 million in 2024.